Prasad L Gawade
Overview
Explore the profile of Prasad L Gawade including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
16
Citations
144
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Rifkin R, Crawford J, Mahtani R, Dale D, Narang M, MacLaughlin W, et al.
Support Care Cancer
. 2022 Jun;
30(10):7913-7922.
PMID: 35732748
Purpose: We evaluated the incidence of febrile neutropenia (FN) and related clinical outcomes among patients treated with myelosuppressive chemotherapy for nonmyeloid malignancies who received pegfilgrastim on-body injector (OBI) or other...
2.
Mahtani R, Belani R, Crawford J, Dale D, Decosta L, Gawade P, et al.
Support Care Cancer
. 2022 Apr;
30(7):6135-6144.
PMID: 35426046
Background: Breast cancer chemotherapy often carries a high risk of febrile neutropenia (FN); guidelines recommend prophylaxis with granulocyte colony-stimulating factor (G-CSF), such as pegfilgrastim. Neulasta Onpro on-body injector (OBI) is...
3.
Mahtani R, Crawford J, Flannery S, Lawrence T, Schenfeld J, Gawade P
BMC Cancer
. 2021 May;
21(1):621.
PMID: 34044798
Background: Pegfilgrastim, a long-acting granulocyte colony-stimulating factor (G-CSF), is commonly used to prevent febrile neutropenia (FN), a potentially life-threatening complication, following myelosuppressive chemotherapy. The FDA label for pegfilgrastim specifies that...
4.
Li S, Peng Y, Liu J, Li S, Raskin L, Kelsh M, et al.
Curr Med Res Opin
. 2020 Jul;
36(9):1519-1527.
PMID: 32715807
Objective: To assess variations in hospitalizations, emergency department/observational (ED/OB) stays not resulting in hospitalization, reasons for hospitalization, and hospitalization discharge destinations after chemotherapy, information not provided as part of Oncology...
5.
Li S, Liu J, Gong T, Guo H, Gawade P, Kelsh M, et al.
J Geriatr Oncol
. 2020 Jul;
11(8):1309-1315.
PMID: 32624415
Purpose: Evaluate the relationship between duration of primary prophylactic short-acting granulocyte colony-stimulating factor (PP-sG-CSF) and risk of neutropenia-related hospitalization (NRH) in older patients receiving myelosuppressive chemotherapy. Methods: Using the Medicare...
6.
Schenfeld J, Bennett C, Li S, DeCosta L, Jaramillo R, Gawade P
J Oncol Pharm Pract
. 2020 Apr;
27(1):128-142.
PMID: 32326872
Purpose: Describe temporal changes in use of myelosuppressive chemotherapy, primary prophylactic colony-stimulating factor, and neutropenia-related hospitalization, in commercially insured patients. Methods: Using a large commercial administrative database, we identified annual...
7.
Gawade P, Li S, Henry D, Smith N, Belani R, Kelsh M, et al.
Support Care Cancer
. 2020 Jan;
28(9):4413-4424.
PMID: 31919669
Purpose: To evaluate patterns of primary prophylactic (PP) granulocyte colony-stimulating factor (G-CSF) use following chemotherapy by cancer type and febrile neutropenia (FN) risk. Methods: Using a commercial administrative database, we...
8.
Hawkins A, Murphy A, McNamara M, Gawade P, Belani R, Kelsh M
J Cancer Educ
. 2019 Oct;
35(1):178-186.
PMID: 31656028
The purpose of the study is to describe oncologists' perceptions and opinions about patient eligibility, guidelines, and barriers for use of granulocyte colony-stimulating factor (G-CSF), overall and stratified by their...
9.
Li S, Liu J, Guo H, Gawade P, Kim C, Bensink M, et al.
Support Care Cancer
. 2019 Oct;
28(6):2637-2649.
PMID: 31624920
Purpose: To assess changes in neutropenia-related hospitalization, myelosuppressive chemotherapy, and primary prophylactic colony-stimulating factor (PP-CSF) use in elderly cancer patients receiving myelosuppressive chemotherapy. Methods: We identified annual cohorts of patients...
10.
Gawade P, Berlin J, Henry D, Tomita D, Brooks B, Franklin J, et al.
Pharmacoepidemiol Drug Saf
. 2017 Aug;
26(11):1357-1366.
PMID: 28809079
Purpose: Evaluate changes in use of erythropoiesis-stimulating agents (ESAs) and red blood cell transfusion in cancer patients receiving myelosuppressive chemotherapy following regulatory and reimbursement actions. Methods: Calendar year patient cohorts...